Cargando…
Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolim...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Association for Laboratory Animal Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219883/ https://www.ncbi.nlm.nih.gov/pubmed/29937473 http://dx.doi.org/10.1538/expanim.18-0042 |
_version_ | 1783368736020889600 |
---|---|
author | Tanaka, Yuji Kimura, Fuminori Zheng, Luyi Kaku, Shoji Takebayashi, Akie Kasahara, Kyoko Tsuji, Shunichiro Murakami, Takashi |
author_facet | Tanaka, Yuji Kimura, Fuminori Zheng, Luyi Kaku, Shoji Takebayashi, Akie Kasahara, Kyoko Tsuji, Shunichiro Murakami, Takashi |
author_sort | Tanaka, Yuji |
collection | PubMed |
description | This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolimus (mTORi), and everolimus plus cisplatin (mTORi+Cis). Mice in the Cis and mTORi+Cis groups were intraperitoneally injected with 2 mg/kg of cisplatin for 15 d. Mice in the mTORi and mTORi+Cis groups were orally administered 2.5 mg/kg of everolimus for 29 d, from one week before the first cisplatin injection to one week after the last cisplatin injection. Histological examinations were performed 24 h after the last everolimus administration. The primordial, primary, and antral follicles were significantly depleted in the Cis group compared with that in the control group, confirming the gonadotoxicity of cisplatin. The number of primordial, secondary, and antral follicles was significantly higher in the mTORi+Cis group than in the Cis group, thereby displaying the effect of mTORi-treatment on ovarian protection. Primordial, secondary, and antral follicle counts were similar in the mTORi+Cis and the control groups. The results of this study indicate a protective effect of an mTOR inhibitor against cisplatin chemotherapy-induced gonadotoxicity in the ovarian reserve in an in vivo mouse model. |
format | Online Article Text |
id | pubmed-6219883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Japanese Association for Laboratory Animal Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-62198832018-11-09 Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity Tanaka, Yuji Kimura, Fuminori Zheng, Luyi Kaku, Shoji Takebayashi, Akie Kasahara, Kyoko Tsuji, Shunichiro Murakami, Takashi Exp Anim Original This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolimus (mTORi), and everolimus plus cisplatin (mTORi+Cis). Mice in the Cis and mTORi+Cis groups were intraperitoneally injected with 2 mg/kg of cisplatin for 15 d. Mice in the mTORi and mTORi+Cis groups were orally administered 2.5 mg/kg of everolimus for 29 d, from one week before the first cisplatin injection to one week after the last cisplatin injection. Histological examinations were performed 24 h after the last everolimus administration. The primordial, primary, and antral follicles were significantly depleted in the Cis group compared with that in the control group, confirming the gonadotoxicity of cisplatin. The number of primordial, secondary, and antral follicles was significantly higher in the mTORi+Cis group than in the Cis group, thereby displaying the effect of mTORi-treatment on ovarian protection. Primordial, secondary, and antral follicle counts were similar in the mTORi+Cis and the control groups. The results of this study indicate a protective effect of an mTOR inhibitor against cisplatin chemotherapy-induced gonadotoxicity in the ovarian reserve in an in vivo mouse model. Japanese Association for Laboratory Animal Science 2018-06-22 2018 /pmc/articles/PMC6219883/ /pubmed/29937473 http://dx.doi.org/10.1538/expanim.18-0042 Text en ©2018 Japanese Association for Laboratory Animal Science This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Tanaka, Yuji Kimura, Fuminori Zheng, Luyi Kaku, Shoji Takebayashi, Akie Kasahara, Kyoko Tsuji, Shunichiro Murakami, Takashi Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity |
title | Protective effect of a mechanistic target of rapamycin inhibitor on an
in vivo model ofcisplatin-induced ovarian
gonadotoxicity |
title_full | Protective effect of a mechanistic target of rapamycin inhibitor on an
in vivo model ofcisplatin-induced ovarian
gonadotoxicity |
title_fullStr | Protective effect of a mechanistic target of rapamycin inhibitor on an
in vivo model ofcisplatin-induced ovarian
gonadotoxicity |
title_full_unstemmed | Protective effect of a mechanistic target of rapamycin inhibitor on an
in vivo model ofcisplatin-induced ovarian
gonadotoxicity |
title_short | Protective effect of a mechanistic target of rapamycin inhibitor on an
in vivo model ofcisplatin-induced ovarian
gonadotoxicity |
title_sort | protective effect of a mechanistic target of rapamycin inhibitor on an
in vivo model ofcisplatin-induced ovarian
gonadotoxicity |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219883/ https://www.ncbi.nlm.nih.gov/pubmed/29937473 http://dx.doi.org/10.1538/expanim.18-0042 |
work_keys_str_mv | AT tanakayuji protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT kimurafuminori protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT zhengluyi protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT kakushoji protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT takebayashiakie protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT kasaharakyoko protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT tsujishunichiro protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity AT murakamitakashi protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity |